SCHEMBL6080533

SCHEMBL6080533

O=C(O)c1cc(O)c2cc(-c3ccccc3Cl)cc(O)c2n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IGFBP3 P17936 2/20 0.43
EGLN1 Q9GZT9 1/20 0.41
EGLN3 Q9H6Z9 1/20 0.41
GPR35 Q9HC97 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
PIK3CA P42336 1/20 0.38
ALPL P05186 1/20 0.38
DHODH Q02127 2/20 0.38
CYP2A6 P11509 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C8 P10632 1/20 0.37
CYP2C9 P11712 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
LTB4R Q15722 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080080 0.83 MCL1 (0.46) KMT2ADHODHKDM4EALDH1A1
SCHEMBL6079795 0.81 ALOX15 (0.48) IGFBP3EGLN1GPR35PIK3CADHODH
SCHEMBL6080194 0.80 KMO (0.51) IGFBP3GPR35KMT2AMEN1DHODH
SCHEMBL6079979 0.80 MCL1 (0.50) IGFBP3GPR35DHODHCYP2A6CYP3A4
SCHEMBL6080200 0.79 GPR35 (0.42) IGFBP3GPR35KMT2AKDM4E
SCHEMBL6079784 0.79 KMO (0.46) EGLN1EGLN3GPR35KMT2AKDM4E
SCHEMBL6080570 0.74 SCN9A (0.43) IGFBP3EGLN1DHODHKDM4E
SCHEMBL6080018 0.74 KMO (0.46) EGLN1GPR35KMT2ADHODHKDM4E
SCHEMBL6080980 0.74 L3MBTL1 (0.53) GPR35DHODHCYP2A6CYP3A4KDM4E
SCHEMBL6080055 0.74 POLB (0.47) EGLN1KMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL IGFBP3 4812/4885EGLN1 1893/4885EGLN3 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.